Opinion|Videos|January 22, 2025

CLEAR-Outcomes Data: Primary Prevention With Bempedoic Acid

Key Takeaways

  • Pediatric lipid screening is vital for early dyslipidemia detection, reducing future cardiovascular disease risk.
  • Guidelines suggest universal screening at ages 9-11 and 17-21, with selective screening for at-risk children.
SHOW MORE

Panelists discuss how the CLEAR-outcomes trial demonstrated bempedoic acid’s efficacy in primary prevention of cardiovascular events, informing its clinical implementation for patients with statin intolerance or inadequate LDL-C control.

Video content above is prompted by the following:

  • The primary prevention data with bempedoic acid from CLEAR-outcomes are exciting. Could you review the data and how you use BA in your practice?

Latest CME